Patents Assigned to GliaMed, Inc.
  • Publication number: 20110218343
    Abstract: This invention relates to neurotrophic compounds having an affinity for FKBP-type immunophilins, their preparation and use as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity.
    Type: Application
    Filed: May 19, 2011
    Publication date: September 8, 2011
    Applicant: GLIAMED, INC.
    Inventors: Gregory S. Hamilton, Joseph Steiner
  • Patent number: 7960570
    Abstract: This invention relates to neurotrophic compounds having an affinity for FKBP-type immunophilins, their preparation and use as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity.
    Type: Grant
    Filed: December 8, 2009
    Date of Patent: June 14, 2011
    Assignee: GliaMed, Inc.
    Inventors: Gregory S. Hamilton, Joseph Steiner
  • Publication number: 20100330063
    Abstract: A new use is provided for small molecule inhibitors of Oct4 and Sox 2 as a cellular reprogramming agent and a method of reprogramming adult mammalian somatic cells into stem-like cells is provided, using small molecule inhibitors of Oct4 and Sox 2 without the need of any material derived from embryos or fetuses, and without the need of potentially harmful transfecting vectors. Stem-like cells created by the present invention can be induced to differentiate into terminally differentiated adult somatic cells, such as, for example, neuronal cells.
    Type: Application
    Filed: December 17, 2008
    Publication date: December 30, 2010
    Applicant: GLIAMED, INC.
    Inventor: David E. Weinstein
  • Publication number: 20100317711
    Abstract: A new use is provided for small molecule inhibitors of Oct4 and Sox 2 as a cellular reprogramming agent and a method of reprogramming adult mammalian somatic cells into stem-like cells is provided, using small molecule inhibitors of Oct4 and Sox 2 without the need of any material derived from embryos or fetuses, and without the need of potentially harmful transfecting vectors. Stem-like cells created by the present invention can be induced to differentiate into terminally differentiated adult somatic cells, such as, for example, neuronal cells.
    Type: Application
    Filed: June 25, 2009
    Publication date: December 16, 2010
    Applicant: GLIAMED, INC.
    Inventor: David E. Weinstein
  • Publication number: 20100145071
    Abstract: This invention relates to neurotrophic compounds having an affinity for FKBP-type immunophilins, their preparation and use as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity.
    Type: Application
    Filed: December 8, 2009
    Publication date: June 10, 2010
    Applicant: GLIAMED, INC.
    Inventors: Gregory S. Hamilton, Joseph Steiner
  • Patent number: 7282510
    Abstract: This invention relates to neurotrophic N-glyoxyl-prolyl ester compounds having an affinity for FKBP-type immunophilins, their preparation and use as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity.
    Type: Grant
    Filed: June 27, 2005
    Date of Patent: October 16, 2007
    Assignee: GliaMed, Inc.
    Inventors: Gregory S. Hamilton, Joseph P. Steiner
  • Patent number: 7253169
    Abstract: The present invention relates to N-substituted cyclic aza compounds, pharmaceutical compositions comprising such compounds, and methods of their use for effecting neuronal activities.
    Type: Grant
    Filed: April 17, 2001
    Date of Patent: August 7, 2007
    Assignee: Gliamed, Inc.
    Inventors: Yong-Qian Wu, Wei Huang, Gregory S. Hamilton
  • Patent number: 7189746
    Abstract: The present invention provides methods for promoting healing of a wound in a and for promoting regeneration of epithelial tissue in a subject comprising administering an effective amount of 2,2?-(1,3,4-oxadiazole-2,5-diyl)bis[1-(3,3-dimethyl-1,2-dioxopentyl)-pyrrolidine (GM-284).
    Type: Grant
    Filed: November 8, 2002
    Date of Patent: March 13, 2007
    Assignee: GliaMed, Inc.
    Inventor: David E. Weinstein